{"id":800864,"date":"2026-07-15T01:33:09","date_gmt":"2026-07-15T01:33:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/800864\/"},"modified":"2026-07-15T01:33:09","modified_gmt":"2026-07-15T01:33:09","slug":"top-broker-just-put-a-buy-rating-on-this-asx-healthcare-share","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/800864\/","title":{"rendered":"Top broker just put a buy rating on this ASX healthcare share"},"content":{"rendered":"<p class=\"wp-block-paragraph\">If you are looking for exposure to the <a href=\"https:\/\/www.fool.com.au\/investing-education\/healthcare-shares\/\" rel=\"nofollow noopener\" target=\"_blank\">healthcare sector<\/a> and have a high tolerance for <a href=\"https:\/\/www.fool.com.au\/investing-education\/understanding-risk-vs-reward\/\" rel=\"nofollow noopener\" target=\"_blank\">risk<\/a>, then it could be worth considering the ASX share in this article.<\/p>\n<p class=\"wp-block-paragraph\">That&#8217;s because the team at Bell Potter believes it could be a buy with huge upside potential.<\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" width=\"1200\" height=\"675\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/01\/shares-buy-16_9-1200x675.jpg\" class=\"attachment-full size-full wp-post-image\" alt=\"Smiling man sits in front of a graph on computer while using his mobile phone.\"  \/><\/p>\n<p>Image source: Getty Images<\/p>\n<p>Which ASX healthcare share?<\/p>\n<p class=\"wp-block-paragraph\">The share that Bell Potter has initiated coverage on this week is Lumos Diagnostics Holdings Ltd (<a class=\"tickerized-link\" href=\"https:\/\/www.fool.com.au\/tickers\/asx-ldx\/\" rel=\"nofollow noopener\" target=\"_blank\">ASX: LDX<\/a>).<\/p>\n<p class=\"wp-block-paragraph\">It is a commercial-stage point-of-care (POC) diagnostics company that is busy developing rapid testing solutions for frontline healthcare settings.<\/p>\n<p class=\"wp-block-paragraph\">Bell Potter believes the company&#8217;s FebriDx product is worth getting excited about. It explains:<\/p>\n<p class=\"wp-block-paragraph\">FebriDx is a rapid POC test built around a simple clinical question, Does the patient have an acute respiratory infection (ARI) requiring antibiotics? Unlike other assays, FebriDx assesses the patient&#8217;s immune response to distinguish bacterial from nonbacterial illnesses after 10 minutes, via a single fingerstick blood sample.\u00a0<\/p>\n<p class=\"wp-block-paragraph\">The dual biomarker (CRP\/MxA) rapid read out supports antibiotic stewardship through real-time decision making that ensures lower and more effective antibiotic use. The journey has been long and has had some setbacks, but now there is a clear path to commercial success following FDA approval with CLIA waiver and reimbursement from CMS that delivers a starting gross margin of 60% and capacity to increase it to 80% over time.<\/p>\n<p class=\"wp-block-paragraph\">The good news is that the broker highlights that this product gives the ASX healthcare share an estimated US$1 billion market opportunity. It adds:<\/p>\n<p class=\"wp-block-paragraph\">The CLIA waiver for FebriDx in March 2026 expanded access to eligible sites by c.8.5x from c.32k to c.277k sites via enabling lower-complexity clinics to perform the FebriDx rapid diagnostic test. The waiver provides access to clinics that are a better fit for FebriDx with lower-complexity front-line settings where FebriDx&#8217;s rapid, analyserfree workflow is better aligned with real-time prescribing decisions. LDX claims it is now exposed to c.80m annual patient visits to Urgent Care \/ Primary Care Physicians which creates a c.US$1b opportunity.<\/p>\n<p>Big potential returns<\/p>\n<p class=\"wp-block-paragraph\">According to the note, the broker has initiated coverage on Lumos Diagnostics shares with a buy rating and 25 cents price target.\u00a0<\/p>\n<p class=\"wp-block-paragraph\">Based on its current share price of 8.6 cents, this implies potential upside of 190% for investors over the next 12 months.<\/p>\n<p class=\"wp-block-paragraph\">Commenting on its initiation, Bell Potter said:<\/p>\n<p class=\"wp-block-paragraph\">We initiate coverage with a BUY recommendation and a 10-yr DCF-based valuation\/ TP of $0.25\/sh, assuming a WACC of 13% and TG of 3.5%. Our TP offers material upside which relies on ensuring deep utilisation by WellStreet and wider adoption of FebriDx over time.<\/p>\n","protected":false},"excerpt":{"rendered":"If you are looking for exposure to the healthcare sector and have a high tolerance for risk, then&hellip;\n","protected":false},"author":2,"featured_media":406358,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500],"class_list":["post-800864","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-au","tag-australia","tag-health","tag-healthcare"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/800864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=800864"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/800864\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/406358"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=800864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=800864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=800864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}